diff options
Diffstat (limited to 'tools/sage.csv')
| -rw-r--r-- | tools/sage.csv | 166 |
1 files changed, 0 insertions, 166 deletions
diff --git a/tools/sage.csv b/tools/sage.csv deleted file mode 100644 index 01ee8017..00000000 --- a/tools/sage.csv +++ /dev/null @@ -1,166 +0,0 @@ -id,name,dependent on -1,Kick-off meeting, -2,Definition of project plan, -3,Definition of roles and responsibilities, -4,Agreement on Data sharing modalities, -5,, -6,Aim 1 - Screen drugs against merlin-deficient VS and M cells, -7,Final list of compounds ready, -8,Assemble 20 to 40 drugs panel, -9,Drugs in hands,8 -10,QC check on purchased drugs,9 -11,MTA negotiation with companies to secure drug supply, -12,"Assemble, test growth rates and choose hum Upfront meningioma lines for M screening set ", -13,Assemble pairs of lines for VS screening set (total 8 lines) Upfront, -14,Optimize assay conditions, -15,Primary Screening of 20 to 40 drugs against both M and VS,"14,11,9" -16,Analysis of data from primary screening,15 -17,Upload of primary screening data into Synapse and report,16 -18,Secondary screening (independent Human M and VS lines) of top drugs,17 -19,Analysis of secondary screening data from secondary screening and interpretation,18 -20,Upload of data into Synapse and reporting - Identification report of active single agents,19 -21,Primary screening of drug combination,"17,58" -22,Upload of primary screening of combination data into report Synapse and reporting,21 -23,Secondary screening of drug combination,"57,21" -24,Upload of secondary screening data into Synapse and report - reporting,23 -25,Selection of drug(s)/Combination(s) for invivo screening,23 -26,Analysis of Human vs Mouse cell lines and selection of winner cell line for NCATS screen,"18,58,60,62" -27,Selection of 'winner' cell line,"26,64" -28,NCATS screening ,27 -29,NCATS hit evaluation,28 -30,Upload of data into Synapse and reporting,29 -31,NCATS hits in primary (or secondary?) screening panels (?),30 -32,Upload of data into Synapse and reporting,31 -33,, -34,, -35,Aim 2 - Collect and Integrate molecular System data to define targets and improve models, -36,Exome/RNA analysis of human NF2-associated tumor at Novartis,"13,12" -37,First deposition of data into the Cancer Cell Line Encyclopedia,36 -38,Report on Novartis's activities at project's meetings,36 -39,Report on Novartis's activities at project's meetings,36 -40,Report on Novartis's activities at project's meetings,36 -41,Report on Novartis's activities at project's meetings,36 -42,Report on Novartis's activities at project's meetings,36 -43,, -44,Availability of data from DoD program at Gusella Lab on Exome scanning and RNAseq of Schwannomas and Meningiomas and upload on Synapse, -45,Upload of consortium members pre-existing data into Synapse, -46,Upload of publicly available data into the Synapse,"44, 45" -47,Transcriptome profile of untreated cell lines (baseline analysis),"12,13" -48,Upload Cell lines baseline characterization only,"13, 47" -49,Transcriptome profile of screening lines control vs treated/responders,17 -50,Upload Control vs treated/responsers,49 -51,Transcriptome profile of screening lines control vs treated/responders of drug combination,"49, 24" -52,Upload Control vs combination's responders,51 -53,Report on transcriptome profiling,52 -54,Jumping Library analysis of structural genomic changes in screening set lines,"12,13" -55,Report on Jumping Library analysis,54 -56,TC call to decide first 6 cell lines to analyse, -57,Kinome analysis of cell lines for baseline characterization ,"56,12,13" -58,Upload of data into Synapse and reporting,57 -59,Kinome analysis of single agent drug responding cell lines,17 -60,Upload of data of single agent drug responding cell lines into Synapse,59 -61,Kinome analysis of combination of drugs responding cell lines,24 -62,Upload of data of combination of drugs responding cell lines into Synapse,61 -63,Report of both single agent and combination responders cell lines,"59, 62" -64,Analysis of integrated system data,"44,37,46,51" -65,Report on analysis of integrated system data - Generate report a list of proposed new targets,"64,68,70" -66,"Target (genes, pathways) validation by shRNA",58 -67,Report on ongoing activities,66 -68,Final Report - ID of new targets for NF2,66 -69,Screening of drugs against validated targets,68 -70,Upload of data into Synapse and reporting,69 -71,Develop CRISP/Cas modified NF2 mutant AC and SC lines,58 -72,Upload of data into Synapse and reporting,71 -73,Develop CRISPR/Cas modified lines bearing cooperating mutations,72 -74,Upload of data into Synapse and reporting,73 -75,Test CRISPR-Cas lines with active drug(s)/combination(s),22 -76,Upload of data into Synapse and reporting,75 -77,RNAseq of genetically mod lines,"65, 72" -78,Upload of data into Synapse and reporting,77 -79,Creation of a new set of genetically-accurate screening panel for NF2,"75, 74" -80,Kinome analysis of invivo tumors,90 -81,Upload of data into Synapse and reporting,80 -82,RNAseq analysis of invivo tumors,90 -83,Upload of data into Synapse and reporting,82 -84,, -85,Aim 3 - Screen drugs invivo in genetically engineered mouse (VS) and xenograft (M) models, -86,Breeding of PeriostinCre; nf2flox/flox mice, -87,Report on first year activities,86 -88,Evaluation of single agent responders for animal studies,"50, 60" -89,Test drug(s)/combination(s) in PeriostinCre; nf2flox/flox mice,"20,88,86" -90,First invivo drug testing (treatment),89 -91,First invivo drug testing (statistics),90 -92,Upload of data into Synapse and reporting,91 -93,Evaluation of single agent responders for animal studies,"52, 62" -94,First invivo combination drug testing (treatment),93 -95,First invivo combination drug testing (statistics),94 -96,Upload of data into Synapse and reporting,95 -97,Last invivo drug testing slot (treatment), -98,Last invivo drug testing (statistics),"89, 97" -99,Upload of data into Synapse and reporting,98 -100,Colony breeding and stereotactic transplantation studies, -101,Report on first year activities,100 -102,Evaluation of single agent responsers for animal studies,88 -103,Test drug(s)/combination(s) in BenMen1 xenograft model,"100, 20, 10" -104,First invivo drug testing,103 -105,Upload of data into Synapse and reporting,104 -106,Evaluation of single agent responders for animal studies,93 -107,First invivo drug testing,106 -108,Upload of data into Synapse and reporting,107 -109,Last invivo drug testing slot,103 -110,Upload of data into Synapse and reporting,109 -111,Prioritize drug(s) for NF2 clinical trials,"80, 82" -112,Supply human tumors, -113,Report on first year activities,112 -114,Report on second year activities,113 -115,Final report,112 -116,Supply human tumors to Novartis for transcriptome and exome analysis and generation of transplantable human, -117,Analysis of human tumors from patients, -118,Report on first year activities,116 -119,Report on second year activities,118 -120,Neuropathological assessment of mouse model tumors,89 -121,Upload of data into Synapse and Final Reporting,120 -122,Generation of transplantable human xenograft,116 -123,Model available to the community (???),122 -124,, -125,Aim 4 - Identify at least 1 drug to move forward for a clinical trial, -126,Evaluation and Design of potential clinical trial(s),111 -127,Clinical trial start,126 -128,, -129,"Aim 5 - Data Sharing, Dissemination plan and management", -130,Setting up of Synapse platform (website, -131,Training of researchers for data input,130 -132,"Data deposition, integration and sharing",131 -133,Report on 1y activities, -134,Report on 2y activities,133 -135,Final report,132 -136,, -137,Project Group calls (bi-weekly), -138,Group call: decision on drug panel, -139,Group call: decision on first cell lines to investigate for kinome and transcriptome profile, -140,Group call: pre-existing data on drugs or cell lines to be uploaded in Synapse, -141,, -142,, -143,, -144,Project Management, -145,Synodos Meeting (kick-off), -146,General management,145 -147,Synodos Meeting(NF conference),146 -148,Synodos Meeting (Ext Review committee),146 -149,First Year report,148 -150,Synodos Meeting(NF conference),146 -151,Synodos Meeting (Ext Review committee),146 -152,Second Year report,151 -153,Synodos Meeting(NF conference),146 -154,Synodos Meeting (Ext Review committee),146 -155,Final report,"154,146" -156,, -157,, -158,, -159,, -160,, -161,, -162,, -163,, -164,, -165,,
\ No newline at end of file |